2026-04-29 Eisai Co.,Ltd. “Regarding sales revenue (preliminary report) for the anti-amyloid-beta protofibril antibody "Rekenbi®".”
2026-04-29 Eisai Co.,Ltd. “Regarding sales revenue (preliminary report) for the anti-amyloid-beta protof … 続きを読む
JP3160400002
2026-04-24 Eisai Co.,Ltd. “A new TV commercial campaign aimed at raising awareness of MCI (Mild Cognitive Impairment) has begun airing nationwide—"Don't Miss It, MCI ~I Was Able to Notice It Early~"—.”
2026-04-24 Eisai Co.,Ltd. “A new TV commercial campaign aimed at raising awareness of MCI (Mild Cognitiv … 続きを読む
2026-04-21 Eisai Co.,Ltd. “An update on the Phase III clinical trial "LITESPARK-012," which evaluates combination therapy as a first-line treatment for patients with advanced renal cell carcinoma (RCC).”
2026-04-21 Eisai Co.,Ltd. “An update on the Phase III clinical trial "LITESPARK-012," which ev … 続きを読む
2026-03-27 Eisai Co.,Ltd. “The European Medicines Agency has accepted the marketing authorization application for the anticancer drug taretrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer. This application will be reviewed for full approval according to the standard schedule. Applications are also planned in other licensed regions of Eisai, including the UK and Canada. Taretrectinib is already approved in the US, China, and Japan for the treatment of advanced ROS1-positive non-small cell lung cancer.”
2026-03-27 Eisai Co.,Ltd. “The European Medicines Agency has accepted the marketing authorization applic … 続きを読む
2026-03-27 Eisai Co.,Ltd. “Regarding "Lenvima®" (lenvatinib), an application has been submitted in Japan to add a new dosage and administration method for combination therapy with "Wellig®" (verzutifan) for renal cell carcinoma that has progressed after cancer chemotherapy.”
2026-03-27 Eisai Co.,Ltd. “Regarding "Lenvima®" (lenvatinib), an application has been submitte … 続きを読む
2026-03-26 Eisai Co.,Ltd. “Notice Regarding the Selection of Directors Candidates.”
2026-03-26 Eisai Co.,Ltd. “Notice Regarding the Selection of Directors Candidates.”
2026-03-26 Eisai Co.,Ltd. “Eisai Co., Ltd.: Personnel changes and organizational restructuring.”
2026-03-26 Eisai Co.,Ltd. “Eisai Co., Ltd.: Personnel changes and organizational restructuring.”
2026-03-25 Eisai Co.,Ltd. “We have released "Hibinoe," a parent-child dialogue facilitating app that supports preparation for future health risks of parents through family conversations—a family app that integrates "understanding the current state of the family, natural conversation, awareness of risks, and how to prepare."”
2026-03-25 Eisai Co.,Ltd. “We have released "Hibinoe," a parent-child dialogue facilitating ap … 続きを読む
2026-03-23 Eisai Co.,Ltd. “Analysis results on the long-term treatment continuation of "Rekenbi®" (lecanemab) in real-world clinical practice in the United States were presented at AD/PD™ 2026—analysis of "Rekenbi" real-world clinical data revealed the patient's choice to continue long-term treatment.”
2026-03-23 Eisai Co.,Ltd. “Analysis results on the long-term treatment continuation of "Rekenbi®&qu … 続きを読む